CURRENT APPROACH TO NON-HODGKIN MANTLE CELL LYMPHOMA: LITERATURE REVIEW
Martina Bogeljić Patekar
Inga Mandac Rogulj
Slobodanka Ostojić Kolonić
APA 6th Edition
Milunović, V., Bogeljić Patekar, M., Mandac Rogulj, I., Planinc-Peraica, A. i Ostojić Kolonić, S. (2016). CURRENT APPROACH TO NON-HODGKIN MANTLE CELL LYMPHOMA: LITERATURE REVIEW. Liječnički vjesnik, 138 (11-12), 0-0. Preuzeto s https://hrcak.srce.hr/173555
MLA 8th Edition
Milunović, Vibor, et al. "CURRENT APPROACH TO NON-HODGKIN MANTLE CELL LYMPHOMA: LITERATURE REVIEW." Liječnički vjesnik, vol. 138, br. 11-12, 2016, str. 0-0. https://hrcak.srce.hr/173555. Citirano 02.10.2023.
Chicago 17th Edition
Milunović, Vibor, Martina Bogeljić Patekar, Inga Mandac Rogulj, Ana Planinc-Peraica i Slobodanka Ostojić Kolonić. "CURRENT APPROACH TO NON-HODGKIN MANTLE CELL LYMPHOMA: LITERATURE REVIEW." Liječnički vjesnik 138, br. 11-12 (2016): 0-0. https://hrcak.srce.hr/173555
Milunović, V., et al. (2016). 'CURRENT APPROACH TO NON-HODGKIN MANTLE CELL LYMPHOMA: LITERATURE REVIEW', Liječnički vjesnik, 138(11-12), str. 0-0. Preuzeto s: https://hrcak.srce.hr/173555 (Datum pristupa: 02.10.2023.)
Milunović V, Bogeljić Patekar M, Mandac Rogulj I, Planinc-Peraica A, Ostojić Kolonić S. CURRENT APPROACH TO NON-HODGKIN MANTLE CELL LYMPHOMA: LITERATURE REVIEW. Liječnički vjesnik [Internet]. 2016 [pristupljeno 02.10.2023.];138(11-12). Dostupno na: https://hrcak.srce.hr/173555
V. Milunović, M. Bogeljić Patekar, I. Mandac Rogulj, A. Planinc-Peraica i S. Ostojić Kolonić, "CURRENT APPROACH TO NON-HODGKIN MANTLE CELL LYMPHOMA: LITERATURE REVIEW", Liječnički vjesnik, vol.138, br. 11-12, str. 0-0, 2016. [Online]. Dostupno na: https://hrcak.srce.hr/173555. [Citirano: 02.10.2023.]
Mantle cell lymphoma (MCL) represents the fourth most common type of non-Hodgkin lymphomas. It is characterized by aggressive course and frequent relapses. The main aim of this review is to evaluate current treatment approach towards this type of lymphoma. In younger patients the chemotherapy including high doses of cytarabine is the gold standard. In case of complete or partial remission, the consolidation with autologous stem cell transplantation is indicated as consolidation approach. In older patients CHOP-R regimen is not the treatment of choice. These patients should be treated with bendamustine in combination with rituximab. In case of complete or partial remission, further therapy with rituximab maintenance as consolidation represents an option. The vast majority of patients with MCL will ultimately relapse which poses a challenge in treatment approach. The approach in relapsed MCL can be divided in two types: chemotherapy or biologic therapy. In young fit patients chemotherapy based on bendamustine and cytarabine is a reasonable option. In patients with comorbidities or poor performance status biologic agents are reasonable options. Ibrutinib, Bruton kinase inhibitor, is characterized by highest overall response rate and the longest duration of response and should be offered to these patients. With the development of novel potent inhibitor of B cell receptor signaling pathway, these agents may become the gold standard in future and introduce the treatment of MCL in „chemo-free“era.
Lymphoma, mantle-cell – therapy, mortality, Antineoplastic combined chemotherapy protocols – therapeutic use, adverse effects, Hematopoietic stem cell transplantation, Transplantation, autologous, Rituximab – therapeutic use, Bendamustine hydrochloride – therapetic use, Pyrazoles – therapetic use, Pyrimidines – therapetic use, Cytarabine – therapeutic use, Biological therapy – methods, Recurrence, Remission induction, Treatment outcome
Posjeta: 2.180 *